Needham & Company
View Older Stories
-
Sarepta Therapeutics (SRPT) PT Lowered to $157 at Needham & Company
-
Needham & Company Reiterates Buy Rating on Sarepta Therapeutics (SRPT) on Positive 5051 Update
-
Pre-Open Stock Movers 11/06: (GPRO) (GLUU) (CSLT) Higher; (ASMB) (TRUE) (STMP) Lower (more...)
-
Companies with NDRs 08/12
-
Sarepta Therapeutics (SRPT) PT Raised to $182 at Needham & Company
-
Needham & Company Reiterates Buy Rating on Sarepta Therapeutics (SRPT)
-
Sarepta Therapeutics (SRPT) PT Lowered to $170 at Needham & Company
-
Sarepta Therapeutics (SRPT) Buy Rating Reiterated At Needham After Exondys Sales Guidance Is Maintained
-
Needham & Company Reiterates Buy Rating on Sarepta Therapeutics (SRPT) Following Update
-
Sarepta Therapeutics (SRPT) PT Lowered to $196 at Needham & Company
-
Sarepta Therapeutics (SRPT) PT Raised to $204 at Needham & Company
-
Sarepta Therapeutics (SRPT) PT Raised to $109 at Needham & Company
-
Sarepta Therapeutics (SRPT): Another Beat and Raise for Exondys - Needham
-
Sarepta Therapeutics (SRPT): Needham & Company Highlights 2 Significant Positive Implications from Dolodiresen Data
-
Sarepta Therapeutics (SRPT) PT Lowered to $75 at Needham & Company; 'FY17 Guidance Significantly Below Expectations'
-
Sarepta Therapeutics (SRPT) PT Lowered to $78 at Needham & Company; PRV Sale Closes Funding Gap
-
Needham & Company Positive on Sarepta (SRPT) Initial Exondys Launch Metrics
-
Sarepta (SRPT) Bullish View Reiterated at Needham & Company on Expanded European DMD Pipeline
-
Sarepta Therapeutics (SRPT) Prices 5.02M Shares at $59.75
-
Sarepta Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock
-
Sarepta Therapeutic (SRPT) PT Raised to $81 at Needham & Company
-
Sarepta (SRPT) PT Raised to $47 at Needham & Company; Sees Upside to $60
-
Sarepta Therapeutics (SRPT) Gains as FDA Update Awaited
-
Pre-Open Stock Movers 04/26: (KN) (TCS) (PETX) Higher; (CPRX) (SRPT) (WHR) Lower (more...)
-
Despite Negative FDA Panel, Needham & Company Sees Approval of Sarepta's (SRPT) Eteplirsen as Early as Next Year
-
Buy Sarepta Therapeutic (SRPT) on Sell-Off - Needham & Company
-
Pre-Open Stock Movers 04/06: (PLCM) (AYI) (SRPT) Higher; (CREE) (TROX) (MAT) Lower (more...)
-
Sarepta's (SRPT) Eteplirsen Supported By Key Opinion Leaders - Needham & Company
-
Streetinsider.com's Hot Lunchtime Reads 11/25: (VRX) (OCN) (SRPT) (MPC)
-
Needham & Company Remains Confident in Sarepta Therapeutic (SRPT) Approval
-
Streetinsider.com's Hot Lunchtime Reads 11/20: (TSLA) (GOOG) (EROS) (VTL) (SRPT)
-
Concerns on Drisapersen Positive for Sarepta's (SRPT) Eteplirsen - Needham & Company
-
Needham & Company Maintain High Conviction for Sarepta (SRPT) Eteplirsen Approval
-
Sarepta Therapeutics Announces Closing of $127 Million Public Offering of Common Stock
-
UPDATE: Sarepta's (SRPT) Prices 3.25M Common Stock Secondary Offering at $39/Share
-
Sarepta Therapeutics Announces Pricing of $127 Million Public Offering of Common Stock
-
Sarepta Therapeutic (SRPT) PT Lifted to $55 at Needham & Company
-
Streetinsider.com's Hot Lunchtime Reads 5/7: (SZYM) (PRGO) (CLI) (ZU) (SRPT)
-
Needham & Company Awaits NDA Filing, Reit Buy on Sarepta Therapeutics (SRPT)
-
Sarepta Therapeutic (SRPT) PT Cut to $38 at Needham & Company; 'Buy' Maintained
-
Pre-Open Stock Movers 02/26: (ELX) (CYBX) (UIL) (CRM) Higher; (CLRX) (LKQ) (TASR) Lower (more...)
-
Pre-Open Stock Movers 11/24: (RNA) (CIMT) (PTP) Higher; (LGF) (TSL) (CBI) Lower (more...)
-
Streetinsider.com's Hot Lunchtime Reads 11/6: (LCI) (TSLA) (STMP) (SRPT)
-
Needham & Company Maintains Bullish View on Sarepta Therapeutic (SRPT) Following Results and Eteplirsen Regulatory Update
-
Sarepta Therapeutic (SRPT) Story Remains Intact, Needham & Company Says
-
Pre-Open Stock Movers 10/01: (TKMR) (HEB) (ANGI) Higher; (FNMA) (FMCC) (WPRT) Lower (more...)
-
Streetinsider.com's Hot Lunchtime Reads 08/07: (TWX) (HIMX) (SRPT) (AAPL)
-
Sarepta Therapeutic (SRPT) Eteplirsen NDA Filing on Track for Year-End, Needham & Company
-
Needham & Company Takes a Closer Look at 144 Week Data for Sarepta's (SRPT) Eteplirsen
-
Sarepta Therapeutic (SRPT) Sell-Off on Confusing WSJ Article 'Unjustified'; Eteplirsen Timelines Intact